SEHK:2162Biotechs
Keymed Biosciences (SEHK:2162) Stock Questions Whether New Profit Can Last
Keymed Biosciences stock has cooled in recent weeks, with the share price down about 10.6% over the past month even after moving into the black over the last year. Today's earnings story is all about profit, not hype. Basic earnings per share for the first half of 2026 came in at ¥4.29, flipping from losses in 2025, and trailing twelve month earnings now support a P/E of 25.4x.
The market is treating that P/E as a question mark. The key issue now is whether investors see this new...